Impact of plasma homocysteine and prothrombin G20210A on primary antiphospholipid syndrome

Blood Coagulation and Fibrinolysis

Volumn 12, Issue 8, 2001, Pages 699-704

  Ames, P R J ^a,b   Margaglione, M ^c   Tommasino, C ^d   Bossone, A ^c   Iannaccone, L ^e   Brancaccio, V ^e  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b WHITTINGTON HOSPITAL   (United Kingdom)

^c CNR   (Italy)

^d San Gennaro Hospital   (Italy)

^e Cardarelli University Hospital   (Italy)

Author keywords

Antiphospholipid antibodies; Homocysteine; Thrombophilic genotypes; Thrombosis

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); HOMOCYSTEINE; PHOSPHOLIPID ANTIBODY; CARDIOLIPIN ANTIBODY; METHYLENE THF REDUCTASE (NADPH); METHYLENE-THF REDUCTASE (NADPH); OXIDOREDUCTASE; PROTHROMBIN;

ADULT; AMINO ACID BLOOD LEVEL; AMINO ACID SUBSTITUTION; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENOTYPE; HOMOZYGOSITY; HUMAN; MALE; PRIORITY JOURNAL; THROMBOPHILIA; THROMBOSIS; BLOOD; CASE CONTROL STUDY; CHI SQUARE DISTRIBUTION; GENETICS; HETEROZYGOTE; ONSET AGE; POINT MUTATION; PREVALENCE;

ADULT; AGE OF ONSET; AMINE OXIDOREDUCTASES; ANTIBODIES, ANTICARDIOLIPIN; ANTIPHOSPHOLIPID SYNDROME; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; FEMALE; HETEROZYGOTE; HOMOCYSTEINE; HUMAN; MALE; MIDDLE AGE; POINT MUTATION; PREVALENCE; PROTHROMBIN; THROMBOPHILIA; THROMBOSIS;

EID: 0035213121     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-200112000-00012     Document Type: Article

References (35)

1. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis
2. New molecular insights into the genetics of thrombophilia
3. 506 → Gln mutation in patients with antiphospholipid antibodies
4. Studies on phospholipid antibodies, APC resistance and associated mutation in the coagulation factor V gene
5. Thrombophilic genotypes in subjects with idiopathic antiphospholipid antibodies. Prevalence and significance
6. The G1691 → A mutation of factor V, but not the G20210 → A mutation of factor II or the C677 → T mutation of methylenetetrahydrofolate reductase genes, is associated with venous thrombosis in patients with lupus anticoagulants
7. Factor V Leiden and venous thrombosis
8. The factor V mutation which predisposes to thrombosis is not common in patients with antiphospholipid antibody syndrome
9. The impact of the search for thrombophilia risk factors among antiphospholipid syndrome patients with thrombosis
10. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis
11. Increased risk for venous thrombosis in carriers of the prothrombin G → A 20210 gene variant
12. The G20210A polymorphism in the 3′-untranslated region of the prothrombin gene in Mexican mestizo patients with primary antiphospholipid syndrome
13. Prothrombin mutation is not associated with thrombosis in patients with antiphospholipid syndrome
14. Molecular genetics analysis in mild hyperhomocysteinaemia: A common mutation in the in methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease
15. A candidate genetic risk factor for cardiovascular disease: A common mutation in methylenetetrahydrofolate reductase
16. A common mutation in methylenetetrahydrofolate reductase gene is not a major risk factor of coronary artery disease or myocardial infarction
17. Thermolabile defect of methylenetetrahydrofolate reductase in coronary artery disease
18. Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine and risk of myocardial infarction in US physicians
19. The use of the dilute Russell viper venom time for the diagnosis of lupus anticoagulants
20. Laboratory diagnosis of lupus inhibitors: A comparison of the tissue thromboplastin inhibition procedure with a new platelet neutralization procedure
21. A rapid screen for lupus anticoagulant (LA) by comparing a sensitive and insensitive aPTT reagent provides also good discrimination from oral anticoagulants, congenital factor deficiency and heparin
22. Elevated total plasma homocysteine and 677C T mutation of the 5,10-methylenetetrahydrofolate reductase gene in thrombotic vascular disease
23. Homocysteine, a risk factor for premature vascular disease and thrombosis, induces tissue factor activity in endothelial cells
24. Enhancement by homocysteine of plasminogen activator inhibitor-1 gene expression and secretion from vascular endothelial and smooth muscle cells
25. Coagulation activation and fibrinolytic imbalance in subjects with idiopathic antiphospholipid antibodies. A crucial role for acquired free protein S deficiency
26. The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome
27. Plasma homocysteine is weakly correlated with plasma endothelin and von Willebrand factor but not with endothelium-dependent vasodilatation in healthy postmenopausal women
28. Homocysteine is related to neopterin and endothelin-1 in plasma of subjects with disturbed glucose metabolism and reference subjects
29. Serum homocysteine is weakly associated with von willebrand factor and soluble vascular cell adhesion molecule 1, but not with C-reactive protein in type 2 diabetic and non-diabetic subjects - The Hoorn study
30. Antiphospholipid antibodies, haemostatic variables and thrombosis. A survey of 144 patients
31. Arterial disease and thrombosis in the antiphospholipid syndrome: A pathogenic role for endothelin 1
32. Induction of monocyte tissue factor expression by homocysteine: A possible mechanism for thrombosis
33. Enhanced in vivo lipid peroxidation at elevated plasma total homocysteine levels
34. "Oxidative stress" in primary antiphospholipid syndrome
35. Anticardiolipin antibody and homocysteine independently predict intima media thickness of carotid arteries in subjects with idiopathic antiphospholipid antibodies